evidences for a cardiovascular function of ghrelin have been reported. Previous studies revealed that chronic administration of ghrelin improved cardiac performance in rats with chronic heart failure, as indicated by increases in cardiac output and left ventricular (LV) fractional shortening (17) and that intravenous bolus infusion of human ghrelin significantly decreased mean arterial pressure in patients with chronic heart failure (16) . However, the precise mechanism of ghrelin actions remains unclear.
On the other hand, left ventricular (LV) remodeling after myocardial infarction (MI) is a major cause of subsequent heart failure and death. The sympathetic nervous system is thought to contribute to the post-MI cardiac dysfunction and remodeling, similar to the renin-angiotensin-aldosterone system (21) . The E-adrenergic blockade, by the suppression of sympathetic activity, has been shown to attenuate the adverse ventricular remodeling seen in heart failure, and decrease mortality (21) (23) . Since recent studies revealed that intracerebroventricular injection of ghrelin decreased renal sympathetic nerve activity in conscious rabbits (15) and suppressed sympathetic nerve activity in brown adipose tissue in rats (24) , we hypothesized that ghrelin might decrease the cardiac sympathetic nerve activity and act against the progression of LV remodeling after MI. Therefore, in the present study, we investigated whether peripheral ghrelin administration attenuates LV dysfunction and remodeling after the early stage of MI and whether the underlying mechanisms are associated with the 
MATERIALS AND METHODS

Model of MI
All experimental procedures were performed according to the National Institutes of Health guidelines for the use of experimental animals and the guidelines for animal experimentation of National Cardiovascular Center. Male Sprague-Dawley rats (Nihon SLC, Hamamatsu, Japan) weighing 180 to 220 g were anesthetized with sodium pentobarbital (30 mg/kg, i.p.). After left thoracotomy, the left coronary artery was ligated 2-3 mm from its origin using a 6-0 Prolene suture. The chest was closed and the rats were allowed to recover. Sham-operated rats underwent the identical surgical procedure without coronary artery ligation.
Administration of ghrelin
From the day after the coronary ligation, the rats with MI were randomly divided into two groups: one to be administered with synthetic rat ghrelin (n=15) and the other with saline as vehicle (n=15). Ghrelin (100µg/kg twice daily, which dose was shown to improve LV function in rats with chronic heart failure (17)) or saline were administered subcutaneously for 2 weeks from the day after the MI operation. The duration of ghrelin administration was chosen based on the mean admission period of 3 weeks in patients with acute MI in our center for future clinical application. The synthetic rat ghrelin was provided by Daiichi Asubio Pharma Co., Ltd. (Tokyo, Japan).
Echocardiographic and hemodynamic studies
Echocardiographic studies were performed using an echocardiography system equipped with a 15 MHz phased-array transducer (SONOS 5500, Hewlett Packard,
Page 4 of 28
Copyright Information
Effect of Ghrelin on Cardiac Remodeling After the administration of ghrelin or saline for 2 weeks, hemodynamic studies were performed. After anesthesia, polyethylene catheter (PE-50) was inserted into the aorta through the right carotid artery for the measurement of heart rate and mean arterial pressure, and the catheter was then advanced into the LV to measure LV pressure.
These hemodynamic variables were measured with a pressure transducer connected to a physiological recorder (PowerLab system, AD Instruments, Mountain View, CA).
After completion of hemodynamic measurements, blood sampling was performed and the hearts were arrested by the injection of 30 mM potassium chloride through the carotid artery, excised, and weighed.
Histological examination and northern blot analysis
The heart were divided from apex to base into four transverse sections (2.0 to 2.2 mm thick), identified as levels 1, 2, 3, and 4, respectively. Levels 1 and 3 were fixed with 4% paraformaldehyde and embedded in paraffin. Levels 2 and 4 were divided into infracted (macroscopic connective tissue) and non-infarcted regions and immediately frozen for the measurement of gene expression. Paraffin sections (2 µm) were stained with Masson's trichrome for measurement of infarct size and Sirius red F3BA for determination of collagen volume fraction. The infarct size was expressed as previously described (11) . To measure collagen volume fraction, 16 fields in the non-infarcted LV walls per section were scanned and computerized with an Optima 6. Total RNA (10 µg/lane) was extracted separately from the non-infarcted region and infarcted region of levels 2 and 4. Hybridization was carried out with cDNA probes for rat J1 (type I) collagen, rat J1 (type III) collagen, rat atrial natriuretic peptide (ANP), and rat glyceraldehydes-3-phosphate dehydrogenase (GAPDH). The band intensity was estimated by a radioimaging analyzer (BAS-5000, Fuji Film, Tokyo, Japan). nervous function was investigated by a power spectral analysis of heart rate variability.
Hormone assays
The heart rate derived from pressure waves was used to generate a power spectral density curve by means of fast-Fourier transform. The range of the low-frequency (LF, 0.04-0.4Hz) or high-frequency (HF, 0.4-1.5Hz) component was chosen on the basis of our preliminary study.
Statistical analysis
All values are expressed as meanዊSEM. Differences among the groups were evaluated by one-way analysis of variance and two-way analysis of variance for repeated measurements, as appropriate. When a statistical difference was detected by analysis of variance, the Bonferroni method of adjusting for multiple pairwise comparisons was used. A value of P<0.05 was considered statistically significant.
RESULTS
The effect of ghrelin on body weight, infarct size, and IGF-1
Body weights of the two MI groups were significantly lower than that of the sham group. However, in rats treated with ghrelin, the decreases in body weights were significantly blunted compared with those given the vehicle (Table 1) . On the other hand, there was no difference of heart weight between ghrelin-and vehicle-treated MI rats. Therefore, the increase in the heart weight-to-body weight ratio after MI, was significantly attenuated in rats treated with ghrelin. As shown in the Table 1, there was no difference of infarct size between the 2 MI groups.
Although growth hormone (GH) is difficult to measure for its instability and the large diurnal change, serum IGF-1, that is secreted from liver in response to GH and more stable than GH in the serum, is readily quantified. Therefore, we measured Table 1) .
The effect of ghrelin on echocardiographic and hemodynamic parameters
Significant thinning of anterior wall and hypertrophy of the posterior wall were observed in the 2 MI groups compared with the sham group after MI. There were no significant differences of these parameters between the vehicle and ghrelin groups even after treatment (Fig. 1a) . Pre treatment, LV diastolic dimension was identical among the 3 groups, and LV fractional shortening was already smaller in MI rats with the vehicle than those in sham rats. In sham rats, these parameters did not change after treatment. In MI rats with the vehicle, the LV enlargement and dysfunction deteriorated progressively during 2 weeks. Post treatment, LV diastolic dimension was significantly smaller in rats treated with ghrelin than in rats with the vehicle.
Furthermore, LV fractional shortening was significantly greater in rats treated with ghrelin than in rats with the vehicle (Fig. 1b) . Table 2 shows hemodynamic assessments after the treatment. The important thing to note is that heart rate was increased in MI rats with the vehicle compared with sham, but ghrelin significantly decreased heart rate to the same level as in the sham group. LV systolic pressure was lower in MI groups with the vehicle and ghrelin than in the sham group, but there was no difference in this parameter between the two MI groups. LV end-diastolic pressure was higher in MI rats with the vehicle than in sham-operated rats. Ghrelin significantly decreased LV end-diastolic pressure.
Maximum and minimum dP/dt were lower in MI rats with the vehicle than in sham rats.
The MI-induced systolic and diastolic LV dysfunction was significantly improved by 
ghrelin.
The effect of ghrelin on cardiac collagen volume and gene expression
To clarify the mechanism of improved cardiac performance caused by ghrelin, we examined the effects of ghrelin treatment on collagen volume in the non-infarcted LV region. Ghrelin markedly attenuated an increase in morphometrical collagen volume fraction in the non-infarcted region in rats with MI (Fig. 2) . To confirm the effects of ghrelin on cardiac remodeling, we examined the expression of several mRNAs associated with heart failure and fibrosis in the non-infarcted LV region. As shown in Fig. 3 , the increased mRNA expressions of ANP, collagen type I and III in MI rats were significantly suppressed by treatment with ghrelin.
The effect of ghrelin on plasma catecholamine concentrations
To further clarify the mechanism of improved cardiac performance caused by ghrelin, we examined the effects of ghrelin on plasma catecholamine concentrations, which reflect sympathetic activation and spillover from nerve endings into circulation. Fig. 4 shows the effects of ghrelin on plasma concentrations of catecholamines.
Plasma noradrenaline concentration was significantly increased in MI rats with the vehicle compared with sham rats. Importantly, ghrelin markedly decreased plasma concentration of noradrenaline to the same level as in the sham group. Although there were no significant differences of adrenaline and dopamine concentrations between the 3 groups, ghrelin tended to decrease these hormone levels.
Acute response of heart rate variability to ghrelin
As shown in Fig. 5 , we next examined the acute effect of ghrelin on the heart rate variability, which has been used to investigate the cardiac autonomic activity separately for the sympathetic and parasympathetic nerves in human and rats. In conscious rats 7
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Effect of Ghrelin on Cardiac Remodeling 10 10 days after MI, heart rate, the low-frequency power (LF) and the low-frequency power to high-frequency power ratio (LF/HF) were higher, and mean arterial pressure was lower than those in sham-operated rats. On the other hand, there was no difference of the high-frequency power (HF) between rats with MI and sham.
Acute administration of ghrelin significantly decreased heart rate in rats with MI, whereas ghrelin did not affect heart rate in sham-operated rats. Ghrelin also tended to decrease mean arterial pressure in rats with and without MI. In conscious rats after MI, acute administration of ghrelin decreased the low-frequency power (LF) and tended to increase high-frequency power (HF) obtained by a telemetry system. Therefore, ghrelin significantly decreased the LF/HF ratio (i.e. cardiac sympathetic activity) in MI rats (Fig. 5) . In sham-operated rats, ghrelin had no substantial effect on heart rate variability. Administration of saline (vehicle) instead of ghrelin did not affect the heart rate variability in rats with MI.
DISCUSSION
The main novel findings of the present study are that continuous administration of ghrelin improved LV dysfunction and attenuated early cardiac remodeling after acute MI. The beneficial effects of ghrelin were accompanied by the suppression of MI-induced increase of heart rate and plasma noradrenaline concentration. In addition, in conscious rats after MI, acute administration of ghrelin decreased the cardiac sympathetic nerve activity, which was examined by heart rate variability using a telemetry system. Taken together, the cardioprotective effects of ghrelin could be mediated by the suppression of cardiac sympathetic nerve activity.
In the present study, LV enlargement induced by MI was significantly attenuated by ghrelin treatment. Moreover, there was a substantial decrease in LV end-diastolic pressure, and increases in dP/dt max/min in ghrelin-treated MI rats compared to saline-treated MI rats. We have previously reported that subcutaneous administration of ghrelin improves LV dysfunction and attenuates the development of LV remodeling in rats with chronic heart failure (17). In the study, ghrelin apparently stimulates the GH/IGF-1 axis, which could induce myocardial growth (1) and, therefore, the beneficial effects of ghrelin could be mediated by the activation of the GH/IGF-1 pathway. In the present study, serum IGF-1 concentration did not increase in MI rats treated with ghrelin and there was no difference of heart weight between MI rats with and without ghrelin. The discrepancy between the present study and the previous study using same daily dose of ghrelin might be due to the different study period (acute-phase and chronic-phase) after MI. In the early phase of MI, serum IGF-1 levels were shown to decrease (5), which is compatible with our results that serum IGF-1 concentration was lower in the 2 MI groups than in the sham group. The neurohumoral changes following MI, which include elevated interleukin-1 and tumor necrosis factor-alpha or reduced IGF-binding proteins, might contribute to the sustained decrease in IGF-1 (8), (7) . The suppressive effects of these factors on IGF-1 might be stronger than the stimulatory effect of exogenous ghrelin on GH/IGF-1 axis. Furthermore, several previous studies suggested that ghrelin has cardioprotective and vasodilatory effects not mediated by GH, because the synthetic GHS-R ligand hexarelin prevented cardiac damage after ischemia-reperfusion even in hypophysectomized rats (14) and vasodilatory effects of ghrelin were not affected by GH release inhibitors (19) . Taken together, we suggests that ghrelin has beneficial effects on early cardiac remodeling and dysfunction after acute MI through GH/IGF-1 independent mechanism.
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Effect of Ghrelin on Cardiac Remodeling 12 12 As shown in Results, ghrelin decreased heart rate to the same level as in the sham group without affecting the arterial pressure in MI rats. In accordance with this result, chronic administration of ghrelin markedly decreased plasma noradrenaline level to the similar level as in the sham group. In addition, in the present study, we found that chronic ghrelin administration significantly attenuated an increase in morphometrical collagen volume fraction in the non-infarcted LV and that the mRNA levels of collagen type I and III in the non-infarcted LV were suppressed by treatment with ghrelin. It may be due in part to the suppression of sympathetic nerve activity by ghrelin, because it has been suggested that norepinephrine regulates synthesis of myocardial type 1 collagen via an indirect effect (3). Since these results suggest the suppression of the sympathetic nervous system in ghrelin-treated MI animals, we next examined the effect of ghrelin on the autonomic nerve activity by the heart rate variability spectra using the telemetry system. In the present study, we have shown for the first time that, in conscious rats after MI, acute administration of ghrelin decreased the activated LF and LF/HF ratio, reflecting sympathetic activity. In contrast, in sham-operated rats, the LF, LF/HF ratio, and heart rate were substantially not affected by ghrelin administration.
Thus, ghrelin may have stronger effect on the activated sympathetic nervous system than on the non-activated system. This hypothesis is supported by our preliminary study that, in sham-operated rats, ghrelin had no significant effects on the body weight, heart weight, and serum IGF-1 concentration (Sham+Ghrelin: body weight 305±4g, heart weight 1.04±0.02g, heart weight/body weight 3.42±0.08, IGF-1 602±17mg/ml).
Since a previous study reported that higher LF and total power were associated with the subsequent LV dilatation in patients with first MI (18) , the suppressive effect of ghrelin on the sympathetic activity could lead to the attenuated LV remodeling in rats with MI.
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The nucleus of the solitary tract, where baroreceptor and chemoreceptor afferent terminate, is one of the most important brain regions to regulate blood pressure and the sympathetic nervous system. (20) A previous study demonstrated that microinjection of ghrelin into the nucleus of the solitary tract elicited dose-related decreases in heart rate and mean arterial pressure and the GHS-R were predominantly present in the nucleus of the solitary tract (13) A recent study suggested that the effects of ghrelin on renal sympathetic nerve activity and blood pressure might be caused via histaminergic system connecting to the brain stem including the nucleus of the solitary tract (22) . In addition, it has been shown that ghrelin produced in the stomach stimulates the gastric vagal afferent nerve and influenced the neuronal activity in the nucleus of the solitary tract (6), resulting in an increase in feeding behavior. Taken together, the present study suggest that peripheral ghrelin might act on the cardiac vagal afferent nerve, which sends projection to the nucleus of the solitary tract, resulting in a decrease in sympathetic activity and heart rate in rats with MI.
Another possibility is that ghrelin has a direct effect on cardiomyocyte not through GH or autonomic nerve system. Some in vitro studies support the direct action of ghrelin on cardiomyocytes. Ghrelin was shown to reduce the doxorubicin-induced mortality of H9c2 cardiomyocytes and endothelial cells (2) , and the Ara C-induced mortality of HL-1 cardiomyocytes. (10) In addition, a recent ex vivo study has shown that administration of ghrelin during ischemia/reperfusion protects against myocardial injury and this effect involve binding to cardiovascular receptors, a process that is upregulated during ischemia/reperfusion.(4) Unfortunately, we could not exclude these possible mechanism of ghrelin's action in the present study. Further studies are necessary to establish the precise mechanism of ghrelin on the in vivo cardiovascular function was investigated by power spectral analysis of heart rate variability, before (Pre), and 1 hr/2hr after ghrelin (100 µg/kg) or saline subcutaneous injection. In conscious rats after MI, acute administration of ghrelin decreased the low-frequency power (LF) and tended to increase high-frequency power (HF), which was accompanied by the significant decrease in heart rate (HR). In sham-operated rats, ghrelin had no substantial effect on LF or HF. Ghrelin did not have a significant effect on mean arterial pressure (MAP) in rats with or without MI. Administration of saline (vehicle) instead of ghrelin did not affect the heart rate variability in rats with MI. **P<0.01, *P<0.05 compared to pre-treatment values.
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